Voriconazole is a triazole compound used to treat fungal infections. These include invasive candidiasis, invasive aspergillosis, and emerging fungal infections.
- Mechanism
- Curator reviewed · 3 references
Voriconazole is used to treat fungal infections caused by a variety of organisms but including Aspergillus spp. and Candida spp. Voriconazole is a triazole antifungal exhibiting fungistatic activity against fungal pathogens. Like other triazoles, voriconazole binds to 14-alpha sterol demethylase, also known as CYP51, and inhibits the demethylation of lanosterol as part of the ergosterol synthesis pathway in yeast and other fungi. The lack of sufficient ergosterol disrupts fungal cell membrane function and limits fungal cell growth. With fungal growth limited, the host's immune system is able to clear the invading organism.
- Primary indication
- For the treatment of esophageal candidiasis, cadidemia, invasive pulmonary aspergillosis, and serious fungal infections caused by Scedosporium apiospermum and Fusarium spp.Curator reviewed · 26 structured indications
- Formula / weight
- C16H14F3N5O · 349.3105 g/mol (avg)
- First approval
- Canada, 2004 · United States, 2002 · European Union, 2016
- Code names
- DRG-0301 · UK-109,496
- Brand names
Resolves to
BCEHBSKCWLPMDN-MGPLVRAMSA-NSMILESC[C@@H](C1=NC=NC=C1F)[C@](O)(CN1C=NC=N1)C1=C(F)C=C(F)C=C1What you can answer from here — as of August 31, 2026
Which drugs share a target with Voriconazole, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account